Alpa Laboratories Limited Overview
Alpa Laboratories is a micro-cap, promoter-controlled Indian manufacturer of pharmaceutical finished dosage forms (FDFs) operating from a single WHO-GMP and ISO 9001-certified multi-dosage plant at Rau, near Indore. It produces injectables (liquid and dry-powder vials and ampoules), tablets, capsules, eye and ear drops, ointments, creams and gels for human use, and boluses, injections and intra-mammary infusions for veterinary use. It earns revenue through four channels: its own "Alpa" branded generics, a veterinary division, exports to emerging markets across Africa, Asia, Latin America and the CIS, and third-party contract manufacturing for domestic majors such as Cipla, Zydus, Lupin and Glenmark. With FY2026 revenue of about INR 106 Cr, virtually no debt and a treasury book of roughly INR 138 Cr that exceeds its market value, the company is better characterised as a cash-rich holding wrapped around a low-margin, sub-scale formulations business whose operating profitability has deteriorated sharply since FY2022.
Company's own description
Across its annual reports and exchange profile, the company describes itself as a WHO-GMP and ISO 9001:2000 certified company that manufactures a wide range of pharmaceutical finished dosage forms under its own brand and for other Indian and multinational companies, with a product range spanning ethical, generic and over-the-counter (OTC) drugs for both human and veterinary use (Screener key points citing alpalabs.in; CRISIL rating rationale, August 2025). For financial reporting, the company treats its entire operation as a single business segment, "Drugs and Chemicals" (FY2023 annual report, as cited by Screener).
What the company does
Alpa manufactures generic formulations in most conventional dosage forms at its Rau facility, which began commercial production in 1999 and has dedicated areas for liquid injections, dry injections, tablets, capsules, eye drops, ear drops, ointments, creams and gels (IIFL company summary; MarketsMojo company CV). Its therapeutic coverage, as summarised in investor-database descriptions derived from company materials, includes anti-infectives (antibacterials, antibiotics, antifungals, antiprotozoals, antivirals), analgesics and anti-inflammatories, cough and cold, cardiovascular, anti-diabetic, nutritional supplements, psychotropics, skin care, and ear and eye care (Investing.com profile).
Business model and revenue model
| Division | Revenue model | Customer type |
|---|---|---|
| Branded Generic Division | Sale of own-brand products under the "Alpa" trademark through distributors, retail chemists, pharmacies and hospitals | Distributors, stockists, hospitals, retail pharmacies (India) |
| Veterinary Division | Sale of animal-health formulations (boluses, injections, intra-mammary infusions) | Veterinary distributors, dairy/livestock channel |
| Exports Division | Sale of formulations to importers and distributors in emerging markets, either under Alpa brands or partner brands | Overseas distributors, government/tender buyers (detail not disclosed) |
| Contract Manufacturing Division | Loan-licence / third-party manufacturing for other pharma companies' brands | Indian pharma companies including Cipla, Zydus Cadila, Lupin, Glenmark, Genom Biotech, Jenburkt |
The business is almost entirely product-based manufacturing revenue. There is no subscription or licensing revenue disclosed. Within product revenue, management historically organised marketing into four divisions (IIFL company summary):
Division-level revenue split: not publicly disclosed in sources accessed.
A material point for analysts: the "Alpa" trademark under which branded products are sold is registered in the name of Alpa Labs (India) Limited, a promoter-group company, not the listed entity (IIFL company summary). The listed company therefore does not own its principal brand asset, creating related-party dependency.
Value-chain position
Alpa sits in the downstream formulation stage: it buys active pharmaceutical ingredients (APIs) and excipients, converts them into finished dosage forms, and sells either into its own distribution channel or to brand owners. It does not manufacture APIs and is not known to conduct original drug discovery. Its economic position is that of a price-taker in commoditised generic molecules (penicillins, albendazole, paracetamol, tinidazole, etc.) where competition is intense and margins are thin.
Independent characterisation
The financial statements tell a story that differs materially from the "pharma manufacturer" label. In FY2025, other income (largely gains on investments) of INR 23.35 Cr was nearly five times operating EBITDA of INR 4.75 Cr (Anand Rathi, FY2025). In FY2026, other income of INR 15.76 Cr compared with operating EBITDA of INR 3.29 Cr. Consolidated investments and short-term securities rose from INR 70.3 Cr (FY2022) to INR 137.9 Cr (FY2026) (StockAnalysis balance sheet). The company has paid no dividend in at least a decade (Finanzen dividend calendar). In effect, the operating business generates modest cash that is accumulated in a growing treasury portfolio, and reported earnings are driven mainly by that portfolio's returns. In Q1 FY2027 (June 2026 quarter), the operating line turned negative (operating loss of INR 3.96 Cr), with other income of INR 5.77 Cr keeping the company profitable (Screener quarterly).
End-markets served
India domestic generics (branded and trade generics); Indian animal health; emerging-market exports (Philippines, Iran, Iraq, Sierra Leone, Madagascar, Kenya, Liberia, Puerto Rico, Haiti, Sudan, Ghana, Nigeria, Sri Lanka per IIFL; also South and Central America, Africa, Asia and CIS countries including Russia, Ukraine and Kazakhstan per Investing.com and Stoxray profiles); and B2B contract manufacturing for Indian pharma majors.
Strategy
Stated strategy
The company does not hold earnings calls, publish investor presentations or host investor days, and no formal medium-term strategy document was found. The FY2025 annual report's Management Discussion & Analysis is largely an industry overview: it frames the global pharma market at USD 1.65 trillion in 2024, growing towards approx. USD 2.35 trillion by 2030, and notes India's pharma exports exceeded USD 30.47 billion in FY2025, up 9% year on year (IIFL reproduction of FY2025 MD&A). Company-specific themes in the FY2025 Directors' Report focus on human-resources practices: competitive compensation benchmarked against peer pharma companies, medical insurance, incentive programmes, long-service awards and employee engagement (IIFL Directors' Report FY2025).
Initiatives in the last 24 months
| Initiative | Date | Detail | Status |
|---|---|---|---|
| Fixed-asset investment | FY2025 | INR 11.4 Cr capex, nearly doubling net PPE; purpose not disclosed | Completed (FY2026 capex fell to INR 4.0 Cr) |
| "Acquisition" disclosure under Reg. 30 | Feb 2025 | Announcement categorised as acquisition; target/value not disclosed in sources accessed | — |
| Board strengthening | Feb 2025 | Executive redesignation of Vitthal Kothana | Completed |
| INR 160 Cr loan/investment authority | 30 Sep 2026 | Shareholders approved authority (likely under Section 186/180 of the Companies Act) of up to INR 160 Cr, which is more than the company's market cap and close to total equity | Approved; deployment not announced |
| Norfolk Mercantile merger | Since Dec 2017 | Simplification of group structure | Pending at NCLT |
Sustainability/ESG commitments, cost programmes with targets and medium-term financial guidance: not publicly disclosed.
Implied strategy (analyst view)
Observed behaviour suggests a conservative, promoter-run strategy: maintain the formulation and contract-manufacturing business at roughly INR 100 to 115 Cr revenue, avoid leverage, and accumulate surplus cash in financial investments rather than distribute it or redeploy it in growth capex. The INR 160 Cr authority approved in September 2026 is the most significant signal of a possible change in capital deployment, but its purpose (inter-corporate loans, investments, guarantees or a strategic transaction) has not been disclosed.
Products & Services
The company does not publish revenue by product, product launch years or pricing. The catalogue below is compiled from product descriptions in investor databases that reproduce the company's product listings (Wright Research; Zonebourse; Investing.com; Stoxray). All products are generic molecules sold in pharmacopoeial grades (IP = Indian Pharmacopoeia; BP = British; USP = United States). Pricing is subject to India's Drug Price Control Order for scheduled molecules; company-specific pricing is not publicly disclosed.
Human health — capsules
| Product | Description / use | Target customer | Notes |
|---|---|---|---|
| Ampicillin Capsules IP/BP | Broad-spectrum penicillin antibiotic | Domestic trade, export tenders | Commodity anti-infective |
| Amoxycillin Trihydrate Capsules IP/BP | Aminopenicillin antibiotic, most widely used oral antibiotic | Domestic trade, exports | High-volume, price-competitive |
| Cloxacillin Capsules IP/BP | Penicillinase-resistant penicillin for staphylococcal infections | Exports, hospitals | — |
| Piroxicam Capsules IP/BP | NSAID for arthritis/pain | Domestic trade, exports | — |
Human health — creams, gels, ointments
| Product | Description / use | Target customer |
|---|---|---|
| Lidocaine Hydrochloride Jelly IP/USP | Topical local anaesthetic (catheterisation, minor procedures) | Hospitals, exports |
| Nitrofurazone Cream USP | Topical antibacterial for burns and wounds | Hospitals, exports |
| Miconazole Cream IP/BP | Topical azole antifungal | Retail, exports |
| Clobetasol Ointment/Cream BP | Super-potent topical corticosteroid | Retail, exports |
Human health — injectables (liquid and dry powder)
| Product | Description / use | Target customer |
|---|---|---|
| Benzylpenicillin Injection IP/BP | Parenteral penicillin G | Hospitals, government/export tenders |
| Benzathine Penicillin Injection IP/BP | Long-acting penicillin (syphilis, rheumatic fever prophylaxis) | Public-health tenders, exports |
| Other liquid and dry-powder vials and ampoules | Facility capability for both forms | Contract-manufacturing clients |
Note: one database lists the two penicillin injections under "ear and eye drops", which appears to be a transcription error; they are classified here as injectables.
Human health — tablets
| Product | Description / use | Target customer |
|---|---|---|
| Albendazole Tablets IP/USP | Broad-spectrum anthelmintic (deworming) | Exports to Africa/Asia, public-health programmes |
| Paracetamol Tablets IP/BP | Analgesic/antipyretic | Domestic trade, exports |
| Tinidazole Tablets IP/BP | Antiprotozoal/antibacterial (amoebiasis, giardiasis) | Domestic trade, exports |
Human health — eye and ear drops
The Rau plant has a dedicated area for eye and ear drops (MarketsMojo company CV). Named SKUs are not publicly disclosed in sources accessed.
Veterinary portfolio
| Product | Form | Use |
|---|---|---|
| Alpamin Bolus | Oral bolus | Mineral/vitamin supplementation for livestock (inferred from name and category; composition not disclosed) |
| Alpazole Bolus | Oral bolus | Anthelmintic (albendazole-class, inferred from name) |
| Atropine Injection B.Vet.C | Injection | Antidote/anticholinergic, British Veterinary Codex grade |
| Intra-mammary infusions | Infusion | Bovine mastitis treatment |
Services
Contract manufacturing: Third-party production of finished dosage forms across the plant's capabilities for Indian pharma companies (Cipla, Zydus Cadila, Lupin, Glenmark, Genom Biotech, Jenburkt, per IIFL). Contract terms, volumes and revenue share: not publicly disclosed.
Discontinued capability
Containment / high-potency oral solids: The Pithampur Unit-II facility (operational 2012) was dedicated to oral hormonal and high-potency formulations. PitchBook records a manufacturing unit of Alpa Laboratories as acquired by Ipca Laboratories on 1 October 2014. The company therefore appears to have exited this higher-value niche.
Financial Narrative
All figures consolidated. Primary data source per table is stated. Blank cells = not publicly disclosed or not computable.
Income statement
Sources: Revenue, operating EBITDA, other income, EBITDA incl. OI from Anand Rathi; gross profit, EBIT, D&A, interest, PBT, tax, net income from StockAnalysis (INR M converted to Cr); EPS from Screener/TipRanks; dividends from Finanzen. Note: TipRanks reports FY2024 EPS as INR 8.01 and Screener INR 7.98 (weighted share-count difference). TipRanks reports a much lower gross profit (INR 18.9 to 19.4 Cr for FY2024-25) using a different cost classification; StockAnalysis figures are used here.
Margins and growth
Derived from table 6.1. Revenue CAGR FY2022 to FY2026 (4 years): approx. -1.5%. Revenue CAGR FY2021 (INR 97.55 Cr) to FY2026 (5 years): approx. +1.6%. Screener reports 5-year compounded sales growth of 2% and 10-year of 7%.
Commentary. The defining trend is the divergence between operating and reported profitability. Gross margin has been broadly stable at 30 to 34%, indicating that raw-material conversion economics have not collapsed; the deterioration sits lower in the P&L. Operating expenses (SG&A plus other operating costs) rose from INR 27.2 Cr in FY2022 to INR 33.9 Cr in FY2025 before easing to INR 30.3 Cr in FY2026 (StockAnalysis), on a revenue base that has not grown. As a result, operating EBIT margin compressed from 8.0% to 1.1% in four years. Net margin, by contrast, rose to a peak of 17.3% in FY2025 because other income (mostly realised gains on the investment portfolio: INR 19.8 Cr in FY2025, INR 9.0 Cr in FY2024, INR 8.8 Cr in FY2022 per StockAnalysis) more than offset the operating decline. By FY2026, other income accounted for 94% of pre-tax profit. The low FY2026 effective tax rate (approx. 10%) also flattered net income; Screener flags the tax rate as "low". The FY2026 inflection is negative on both operating and treasury lines, and Q1 FY2027 showed an outright operating loss despite 25% revenue growth, implying adverse product mix, pricing pressure or cost overruns not explained in public disclosures.
Balance sheet
Sources: StockAnalysis balance sheet (INR M converted); equity and borrowings from Screener (rounded to whole crore). Short-term debt derived as total borrowings minus long-term debt. Net debt derived as total borrowings minus cash and short-term investments. Book value per share derived from equity over 2.104 Cr shares; Screener reports INR 88.5 for FY2026.
Working capital (derived). Current liabilities are not separately reported in sources accessed. Using Screener's "other liabilities" plus borrowings as an upper-bound proxy for current liabilities gives approximate working capital of INR 104 Cr (FY2022), INR 117 Cr (FY2023), INR 131 Cr (FY2024), INR 141 Cr (FY2025) and INR 155 Cr (FY2026). The bulk of this is the treasury portfolio rather than operating working capital.
Commentary. The balance sheet has strengthened steadily: equity grew 52% from INR 122 Cr to INR 186 Cr in four years entirely through retained earnings, since no dividends were paid and no shares issued. The treasury portfolio nearly doubled. Operating assets remain modest; net PPE stepped up from INR 11.4 Cr to INR 20.6 Cr in FY2025 following INR 11.4 Cr of capex (the purpose of which is not disclosed in sources accessed). Goodwill is negligible. Receivables are high relative to sales (debtor days 141 in FY2026), a long-standing feature consistent with contract-manufacturing and export credit terms.
Cash flow
Source: StockAnalysis cash flow statement (INR M converted). Screener's rounded figures (CFO INR 10, 9, 4, 18, 9 Cr; FCF INR 8, 8, -3, 7, 6 Cr) are consistent.
Commentary. Operating cash flow is volatile and heavily influenced by working-capital swings. The FY2025 spike to INR 18.3 Cr was driven by a INR 20.4 Cr increase in payables, i.e. stretching suppliers, rather than by underlying profitability (operating EBITDA was only INR 4.75 Cr that year). Cumulative five-year FCF of approx. INR 25.7 Cr compares with cumulative reported net income of INR 78 Cr; the gap reflects that most reported profit is non-cash or investment-related gains that are recycled within the portfolio. None of the cash generated has been returned to shareholders.
Ratios
Sources: ROCE, debtor/inventory/payable days and CCC from Screener ratios. ROE, ROA, D/E, net debt/EBITDA, interest coverage and asset turnover derived from tables 6.1 and 6.3 using average balances (FY2021 equity INR 108 Cr and total assets INR 140 Cr from Screener). Operating ROIC derived as EBIT excl. OI divided by (equity + borrowings - cash & short-term investments), averaged; this isolates the operating business. Screener reports FY2026 ROE as 8.38%; MarketInOut reports a ROIC of -1.58% on a TTM basis.
Commentary. Headline ROE of 8 to 12% conceals two very different businesses. The operating business's pre-tax return on the capital actually deployed in it has fallen from approx. 13% to approx. 1%, which is below any reasonable cost of capital. The treasury portfolio, which represents more than half of total assets, is earning the remainder. Asset turnover has halved partly because idle treasury assets swell the denominator. Interest coverage has declined sharply but debt is trivial, so solvency risk is negligible. The CRISIL B rating reflects information non-cooperation rather than financial stress.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Relationship | Status |
|---|---|---|
Alpa Laboratories Limited | Listed parent | Operating company |
Norfolk Mercantile Private Limited | 100% subsidiary (acquired FY2014-15) | Merger into parent pending before NCLT Mumbai since 7 Dec 2017 |
Alpa Labs (India) Limited | Promoter-group company (not a subsidiary) | Registered owner of "Alpa" trademark |
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Segment revenue Drugs and Chemicals (INR Cr) | 112.27 | 92.44 | 108.74 | 112.45 | 105.81 |
Segment operating EBITDA excl. other income (INR Cr) | 10.69 | 7.56 | 8.11 | 4.75 | 3.29 |
Segment EBITDA margin (%) | 9.5 | 8.2 | 7.5 | 4.2 | 3.1 |
YoY revenue growth (%) | 15.1 | -17.7 | 17.6 | 3.4 | -5.9 |
Contribution to total revenue (%) | 100 | 100 | 100 | 100 | 100 |
Revenue History
| Quarter | Sales | Operating profit | OPM % | Other income | PBT | Net profit |
|---|---|---|---|---|---|---|
Jun 2024 (Q1 FY25) | 21.44 | 0.53 | 2.5 | 5.16 | 5.10 | 5.10 |
Sep 2024 (Q2 FY25) | 24.94 | 3.32 | 13.3 | 6.91 | 9.65 | 7.69 |
Dec 2024 (Q3 FY25) | 26.15 | 0.74 | 2.8 | 8.80 | 8.90 | 8.90 |
Mar 2025 (Q4 FY25) | 39.92 | 0.20 | 0.5 | 2.48 | 2.08 | -2.12 |
Jun 2025 (Q1 FY26) | 19.11 | 0.43 | 2.3 | 11.94 | 11.77 | 11.77 |
Sep 2025 (Q2 FY26) | 26.26 | -2.25 | -8.6 | 3.06 | 0.11 | 0.11 |
Dec 2025 (Q3 FY26) | 29.05 | 1.51 | 5.2 | 0.91 | 1.74 | 1.59 |
Mar 2026 (Q4 FY26) | 31.40 | 3.60 | 11.5 | -0.16 | 3.07 | 1.38 |
Jun 2026 (Q1 FY27) | 23.93 | -3.96 | -16.6 | 5.77 | 0.98 | 0.98 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 112.27 | 92.44 | 108.74 | 112.45 | 105.81 |
Gross profit (INR Cr) | 36.16 | 31.29 | 34.14 | 36.41 | 31.51 |
Operating EBITDA excl. other income (INR Cr) | 10.69 | 7.56 | 8.11 | 4.75 | 3.29 |
Other income (INR Cr) | 10.78 | 9.93 | 14.89 | 23.35 | 15.76 |
EBITDA incl. other income (INR Cr) | 21.46 | 17.49 | 23.00 | 28.10 | 19.05 |
Depreciation & amortisation (INR Cr) | 1.66 | 1.33 | 1.96 | 2.20 | 2.09 |
Operating income EBIT excl. other income (INR Cr) | 9.01 | 6.76 | 6.66 | 2.50 | 1.20 |
Interest expense (INR Cr) | 0.11 | 0.08 | 0.36 | 0.23 | 0.26 |
Pre-tax income (INR Cr) | 19.56 | 15.89 | 20.68 | 25.67 | 16.70 |
Income tax (INR Cr) | 5.47 | 3.31 | 3.91 | 6.16 | 1.69 |
Net income (INR Cr) | 14.09 | 12.58 | 16.78 | 19.50 | 15.01 |
EPS basic (INR) | 6.70 | 5.98 | 7.98 | 9.27 | 7.13 |
EPS diluted (INR) | 6.70 | 5.98 | 7.98 | 9.27 | 7.13 |
Dividend per share (INR) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | 32.2 | 33.7 | 31.4 | 32.4 | 29.8 |
Operating EBITDA margin excl. OI (%) | 9.5 | 8.2 | 7.5 | 4.2 | 3.1 |
Operating EBIT margin (%) | 8.0 | 7.3 | 6.1 | 2.2 | 1.1 |
Net margin (%) | 12.5 | 13.6 | 15.4 | 17.3 | 14.2 |
Other income as % of PBT | 55.1 | 62.5 | 72.0 | 91.0 | 94.4 |
Revenue growth YoY (%) | 15.1 | -17.7 | 17.6 | 3.4 | -5.9 |
Net income growth YoY (%) | 94.4 | -10.7 | 33.4 | 16.2 | -23.0 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (INR Cr) | 155.2 | 167.3 | 182.4 | 222.6 | 242.1 |
Cash & equivalents (INR Cr) | 1.58 | 8.81 | 1.71 | 2.22 | 2.84 |
Cash + short-term investments/trading securities (INR Cr) | 70.27 | 80.84 | 92.85 | 112.70 | 137.90 |
Long-term investments (INR Cr) | 7.47 | 7.77 | 8.27 | 8.77 | 6.62 |
Accounts receivable (INR Cr) | 38.04 | 46.73 | 41.15 | 46.83 | 40.83 |
Inventory (INR Cr) | 15.46 | 12.64 | 13.67 | 17.64 | 13.33 |
Net property, plant & equipment (INR Cr) | 9.22 | 6.96 | 11.41 | 20.60 | 20.12 |
Goodwill & intangibles (INR Cr) | 0.10 | 0.08 | 0.06 | 0.05 | 0.04 |
Total current assets (INR Cr) | 138.0 | 149.1 | 161.0 | 192.5 | 210.9 |
Accounts payable (INR Cr) | 14.92 | 15.06 | 11.78 | 18.69 | 17.79 |
Total borrowings (INR Cr) | 6 | 2 | 5 | 0 | 3 |
Long-term debt (INR Cr) | 2.13 | 0.78 | 0 | 0 | 0 |
Short-term debt (INR Cr, derived) | 3.87 | 1.22 | 5 | 0 | 3 |
Net debt (INR Cr; negative = net cash) | -64.3 | -78.8 | -87.9 | -112.7 | -134.9 |
Shareholders' equity (INR Cr) | 122 | 135 | 152 | 172 | 186 |
Book value per share (INR) | 58.0 | 64.2 | 72.2 | 81.7 | 88.4 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (INR Cr) | 9.94 | 8.90 | 3.65 | 18.32 | 9.95 |
Capital expenditure (INR Cr) | -2.19 | -1.13 | -6.39 | -11.38 | -3.95 |
Free cash flow (INR Cr) | 7.75 | 7.77 | -2.74 | 6.94 | 6.00 |
Net purchase of investment securities (INR Cr) | -19.18 | -0.03 | -9.51 | -3.39 | -10.35 |
Dividends paid (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Change in receivables (INR Cr) | 7.59 | -6.64 | 5.25 | -7.59 | 5.60 |
Change in payables (INR Cr) | -8.20 | 1.98 | -3.71 | 20.40 | -0.90 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE (%) | 12.6 | 9.8 | 11.7 | 12.0 | 8.4 |
ROA (%) | 9.5 | 7.8 | 9.6 | 9.6 | 6.4 |
ROCE (%) | 9 | 12 | 15 | 16 | 9 |
Operating ROIC excl. treasury, pre-tax (%) | 13.1 | 9.3 | 8.3 | 2.7 | 1.3 |
Current ratio (x, derived proxy) | 4.1 | 4.7 | 5.4 | 3.8 | 3.8 |
Debt / equity (x) | 0.05 | 0.01 | 0.03 | 0.00 | 0.02 |
Net debt / EBITDA incl. OI (x) | -3.0 | -4.5 | -3.8 | -4.0 | -7.1 |
Interest coverage EBIT excl. OI / interest (x) | 84 | 81 | 19 | 11 | 5 |
Asset turnover (x) | 0.76 | 0.58 | 0.62 | 0.56 | 0.45 |
Debtor days | 124 | 184 | 138 | 155 | 141 |
Inventory days | 81 | 84 | 73 | 92 | 73 |
Payable days | 78 | 100 | 63 | 97 | 98 |
Cash conversion cycle (days) | 127 | 168 | 149 | 150 | 116 |
Revenue by Region
| Region | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Total revenue (INR Cr) | 108.74 | 112.45 | 105.81 |
Valuation Snapshot
| Metric | Value | Source |
|---|---|---|
Last price (1 Oct 2026) | INR 59.3 | Screener |
52-week high / low | INR 99.8 / INR 46.0 | Screener |
1-year return | -33% | Screener |
3-year CAGR | -8% | Screener |
5-year CAGR | +1% | Screener |
10-year CAGR | +6% | Screener |
All-time reference | 5-year low INR 11.20 and 5-year high INR 144.50 (as of Mar 2025) | Equentis |
Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
EPS (INR) | 6.70 | 5.98 | 7.98 | 9.27 | 7.13 |
Book value per share (INR) | 58.0 | 64.2 | 72.2 | 81.7 | 88.4 |
Dividend per share (INR) | 0 | 0 | 0 | 0 | 0 |
Valuation Multiples
| Multiple | Alpa | Basis |
|---|---|---|
P/E (TTM) | 30.7x | Screener (TTM EPS INR 1.94) |
P/E (FY2026) | 8.3x | INR 59.3 / FY2026 EPS INR 7.13 (derived) |
P/B | 0.67x | Screener |
EV/Sales | approx. -0.1x | EV approx. INR -10 Cr (market cap INR 125 Cr + debt INR 3 Cr - cash/ST investments INR 137.9 Cr) (derived) |
Credit Ratings
| Agency | Facility | Amount (INR Cr) | Rating | Outlook | Date |
|---|---|---|---|---|---|
CRISIL | Cash credit (long term) | 14 | CRISIL B (Issuer Not Cooperating) | Stable | 29 Aug 2025 |
CRISIL | Bank guarantee (short term) | 1 | CRISIL A4 (Issuer Not Cooperating) | — | 29 Aug 2025 |
CRISIL | Letter of credit (short term) | 1 | CRISIL A4 (Issuer Not Cooperating) | — | 29 Aug 2025 |
Moody's / S&P / Fitch | — | — | Not rated | — | — |
Analyst Conclusions
Management guidance
None. The company provides no financial guidance, holds no earnings calls and publishes no investor presentations.
Consensus expectations
No consensus estimates exist.
Bull case
-
Asset backing exceeds price. Liquid investments of INR 137.9 Cr (FY2026) exceed market cap of approx. INR 125 Cr, and total book equity of INR 186 Cr implies a 33% discount. Investors effectively receive the operating business, plant and INR 20 Cr of PPE for free.
-
Operating recovery potential. Q1 FY2027 revenue grew 25.2% YoY; with gross margins still at approx. 30% and newly expanded capacity (FY2025 capex INR 11.4 Cr), restoring opex discipline to FY2022 levels could return operating EBITDA to INR 10 Cr or more.
-
Catalyst optionality. The INR 160 Cr authority, a long-overdue Norfolk merger completion, or a first-ever dividend could unlock the treasury discount.
Bear case
-
Operating business is value-destructive. Operating ROIC fell to approx. 1% in FY2026 and turned negative in Q1 FY2027, with no disclosed plan to fix it.
-
Cash may never reach minorities. No dividend in a decade, a promoter-owned brand, CRISIL non-cooperation and frequent compliance-officer turnover suggest the treasury discount is rational, and the new INR 160 Cr authority raises the risk of related-party or non-core deployment.
-
Earnings are market-dependent. With 90%+ of PBT from investment income, reported EPS could fall sharply in a weak equity or debt market, and TTM P/E is already 30.7x.
Catalysts and monitorables (next 12 months)
-
Q2 FY2027 results (expected around 12 November 2026): whether operating losses persist after the Q1 FY2027 loss.
-
Disclosure of the purpose of the INR 160 Cr loan/investment authority and any inter-corporate loans or investments made under it.
-
Composition of the treasury portfolio (equity versus debt funds) and realised gains.
-
Any dividend or buyback announcement.
-
Norfolk Mercantile NCLT outcome.
-
Stability of the company secretary/compliance function.
-
Promoter shareholding changes (57.19% at June 2026).
-
CRISIL rating review (typically around August).
Analyst verdict
Alpa Laboratories is not, in substance, the pharmaceutical growth story its sector label implies. It is a micro-cap holding company in which a single-site generic formulations plant generating roughly INR 100 to 115 Cr of revenue is attached to a liquid investment portfolio that has grown to about INR 138 Cr, larger than the company's entire market value. The operating franchise has eroded steadily: operating EBITDA margin fell from 9.5% in FY2022 to 3.1% in FY2026, and the June 2026 quarter produced an operating loss of nearly INR 4 Cr even as revenue rose by a quarter. Reported profits and headline ROE have been sustained almost entirely by investment income, which accounted for more than 90% of pre-tax profit in each of the last two fiscal years.
The stock's discount to book (0.67x) and to its own cash pile is therefore not an obvious mispricing. It reflects a decade without a dividend, a primary trademark owned by a promoter-group entity, a credit-rating relationship classified as non-cooperative for four years running, an intra-group merger stalled at the NCLT since 2017, and rapid turnover of compliance officers. The September 2026 shareholder approval of an INR 160 Cr loan and investment authority, exceeding the company's market capitalisation, is the pivotal open question: deployed into an accretive acquisition or returned to shareholders, it could close the discount; deployed into related or non-core assets, it would confirm the market's scepticism.
On balance, the evidence supports a cautious stance. The downside is cushioned by hard asset backing and a debt-free balance sheet, so permanent capital loss risk appears limited at current prices, but there is no visible catalyst for re-rating within management's demonstrated behaviour. Investors should treat the shares as a deep-value, governance-dependent special situation, and should require concrete evidence of capital return or an operating turnaround, most immediately in the November 2026 results and in the use of the new borrowing authority, before taking a constructive view.
Principal sources: NSE/BSE exchange filings (results for quarters ended Sep 2025 and Dec 2025; AGM outcomes; Reg. 30 disclosures); Alpa Laboratories annual reports FY2022, FY2024 and FY2025 (via BSE and IIFL); CRISIL rating rationale, 29 Aug 2025; Screener.in consolidated financials and shareholding (accessed Oct 2026); StockAnalysis (income statement, balance sheet, cash flow FY2022-FY2026); Anand Rathi financial results; Kotak Neo quarterly results; TipRanks; IIFL/IndiaInfoline company summary; MarketsMojo company CV; MarketScreener event log; PitchBook; Fyers peer data; Finanzen dividend calendar; Morningstar; Investing.com; Univest (Q1 FY2027).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Category | Tenure / notes | Source |
|---|---|---|---|---|
Mahendra Singh Chawla | Chairman | Promoter, director | Chairman in FY2022 and FY2024 annual reports; signs AGM notices | BSE annual reports FY2022, FY2024; Nirmal Bang |
Paresh Chawla | Managing Director | Promoter, executive (DIN 00520411) | MD; reappointment approved at 38th AGM, 30 Sep 2026; largest individual shareholder at 34.26% | MarketsMojo; Screener announcements; FY2022 AR |
Pravin Shah | Director | Promoter-group/non-independent (Shah family of founding partners, inferred) | Board member in FY2022 and FY2024 ARs | BSE ARs |
Shitul Shah | Director | Non-independent | Board member per FY2024 AR | BSE AR FY2024 |
Vitthal Kothana | Executive Director / Whole-time Director | Executive | Appointed director c. 2022 (FY2022 AGM resolution); redesignated executive director 14 Feb 2025 | FY2022 AR; MarketScreener |
Sanket Baheti | Independent Director | Independent | Per FY2024 AR | BSE AR FY2024 |
Pratibha Lunawat | Independent Director | Independent | Per FY2024 AR | BSE AR FY2024 |
Jyoti Jain | Independent Director | Independent | Listed in both FY2022 and FY2024 ARs | BSE ARs |
Devendra Baheti | Independent Director (former) | Independent | Listed in FY2022 AR; not in FY2024 AR | BSE AR FY2022 |
Additional / new independent director | Independent | Independent | An independent director appointment was approved at the 30 Sep 2026 AGM; name not confirmed in sources accessed | Screener announcements |
Diksha Jaswani | Company Secretary & Compliance Officer | KMP | Appointed 17 Sep 2026 | Screener announcements |
Chief Financial Officer | KMP | — | Name not publicly disclosed in sources accessed | — |
Board & Management Changes
| Date | Event | Source |
|---|---|---|
10 Dec 2024 | Swati Bagh resigns as Company Secretary & Compliance Officer (announced 14 Nov 2024) | MarketScreener |
13 Feb 2025 | Srashti Chopra appointed Company Secretary & Compliance Officer | MarketScreener |
14 Feb 2025 | Vitthal Kothana redesignated non-executive to executive director | MarketScreener |
25 Mar 2026 | Srashti Chopra resigns | MarketScreener |
11 Apr 2026 | Yashoda Patidar appointed Company Secretary & Compliance Officer | Screener |
26 Jul 2026 | Yashoda Patidar resigns | MarketScreener |
17 Sep 2026 | Diksha Jaswani appointed Company Secretary & Compliance Officer | Screener |
30 Sep 2026 | MD reappointment and independent director appointment approved at AGM | Screener |
Shareholding Trend
| Holder category | Sep 2025 (%) | Dec 2025 (%) | Mar 2026 (%) | Jun 2026 (%) |
|---|---|---|---|---|
Promoters | 57.29 | 57.29 | 57.19 | 57.19 |
Foreign institutional investors | 0.35 | 0.36 | 0.38 | 0.35 |
Domestic institutional investors | 0.00 | 0.00 | 0.00 | 0.07 |
Public | 42.36 | 42.35 | 42.43 | 42.38 |
Number of shareholders | 18,542 | 18,236 | 17,900 | 17,643 |
Competitive Landscape
Competitors by Segment
| Activity | Named competitors | Positioning versus Alpa |
|---|---|---|
Contract / third-party FDF manufacturing | Akums Drugs & Pharmaceuticals; Synokem Pharmaceuticals (private); Innova Captab; Medicamen Biotech | Much larger scale and broader dosage portfolios; Alpa is a niche, single-site supplier |
Branded/trade generics (India) | Lincoln Pharmaceuticals; Bal Pharma; Kopran; Brooks Laboratories | Similar small-cap profile; most have larger domestic field forces |
Emerging-market exports | Lincoln Pharmaceuticals; Kopran; Marksans Pharma; Medicamen Biotech | Peers have regulated-market approvals or larger export books |
Veterinary formulations | Zydus Animal Health (Zydus Lifesciences); Intas Animal Health (private); Hester Biosciences | Market dominated by larger specialist players |
Indian pharma majors (also customers) | Sun Pharma; Cipla; Zydus Lifesciences; Lupin; Dr Reddy's; Aurobindo | Customers and competitors; incomparably larger |
Peer Comparison FY2026
| Company | Market cap (INR Cr) | P/E (x) | Annual PAT (INR Cr) |
|---|---|---|---|
Sun Pharma | 456,833 | 37.8 | 11,479 |
Zydus Lifesciences | 113,217 | 25.1 | 5,040 |
Cipla | 112,212 | 33.3 | 3,879 |
Lupin | 97,626 | 17.7 | 5,333 |
Alpa Laboratories | 134 | 30.7 | 15 |



